Clinical Trial Update: Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy [Phase 2]

View source ↗

Summary

Clinical trial update for enfortumab vedotin in advanced small bowel adenocarcinoma patients refractory or intolerant to platinum therapy (Phase 2), currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Bowel Adenocarcinoma

Drugs mentioned

• Padcev (enfortumab vedotin)

Snippet

Sponsor: National Cancer Center, Japan | Conditions: Advanced Small Bowel Adenocarcinoma | Phase 2 | Status: RECRUITING